Removing Race Correction From Lung Function Test Changes Clinical Management
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
WEDNESDAY, Aug. 30, 2023 -- Removal of race correction from pulmonary function tests (PFTs) may change surgical management of lung cancer in African American patients, according to a study published Aug. 16 in JAMA Surgery.
Sidra N. Bonner, M.D., M.P.H., from the University of Michigan in Ann Arbor, and colleagues aimed to identify how many hospitals providing lung cancer surgery use race correction, examined the association of race correction with predicted lung function, and tested the effect of hypothetical vignettes on surgeons’ treatment recommendations for African American patients. The analysis included data from 515 African American patients who underwent lung cancer resection between Jan. 1, 2015, and Sept. 31, 2022.
The researchers found that 15 of 16 hospitals performing lung cancer resection for African American patients in Michigan reported using race correction, corresponding to 91.8 percent of African American patients having race-corrected PFTs. If race-neutral equations had been used, the percent predicted preoperative forced expiratory volume in 1 second (FEV1) and postoperative FEV1 would have decreased by 9.2 percent (P < 0.001) and 7.6 percent (P < 0.001), respectively. Among 225 cardiothoracic surgeons who completed treatment recommendations based on a randomized vignette, surgeons randomly assigned to the vignette with African American race-corrected PFTs were more likely to recommend lobectomy (79.2 percent) versus surgeons randomly assigned to the other race or multiracial-corrected vignette (61.7 percent; P = 0.02) or race-neutral PFTs (52.8 percent; P = 0.001).
“It is important that race-correction in spirometry tests is removed given that it is based on the flawed concept of race as a biological factor,” Bonner said in a statement. “For African Americans with lung cancer being evaluated for surgery, this may exacerbate existing disparities in lung cancer care.”
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted August 2023
Read this next
High Level of Approval Observed for Polygenic Embryo Screening
FRIDAY, May 17, 2024 -- There is a high level of approval for use of polygenic embryo screening, according to a study published online May 14 in JAMA Network Open. Rémy A...
AI Chatbots Can Generate Quality, Empathetic, Readable Responses
FRIDAY, May 17, 2024 -- For patient questions about cancer, artificial intelligence (AI) chatbots can generate quality, empathetic, and readable responses, according to a study...
Perioperative Nivolumab Tops Chemo for Survival in Resectable Lung Cancer
FRIDAY, May 17, 2024 -- For patients with resectable non-small cell lung cancer (NSCLC), perioperative treatment with nivolumab results in significantly longer event-free...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.